BioSpace News Archive

IceCure Medical Ltd. (Nasdaq: ICCM) (“IceCure” or the “Company”) today announced it will participate in the Cardiovascular and Interventional Radiology Society of Europe (CIRCE) 2023 Annual Congress in Copenhagen, Denmark on September 9 – 13, 2023.

Seres Therapeutics, Inc. (Nasdaq: MCRB) (“Seres” or the “Company”), a leading microbiome therapeutics company, today announced that on September 6, 2023, the Compensation and Talent Committee of Seres’ board of directors granted inducement equity grants covering an aggregate of 91,000 shares of its common stock to two new employees.

Ardelyx, Inc. (Nasdaq: ARDX) today announced that Mike Raab, president and chief executive officer of Ardelyx, will present at the H.C. Wainwright 25th Annual Global Investment Conference on Monday, September 11, 2023, at 12:00 p.m. ET in New York City.

BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that on September 06, 2023, the compensation committee of BridgeBio’s board of directors granted twenty-four new employees restricted stock units for an aggregate of 154,186 shares of the Company’s common stock.

SK bioscience announced that Ana Brnabić, Prime Minister of the Republic of Serbia has visited the SK bioscience headquarters and signed a memorandum of understanding with the company to establish a strategic partnership in vaccine development and manufacturing between the two countries.

PurMinds NeuroPharma (“PurMinds” or the “Company”), a Canadian neuroscience company with a robust clinical pipeline combining small molecules, psychedelic compounds and other modalities, pursuing breakthrough therapeutic solutions for neurological disorders marred by neurodegeneration

Yaron Tomer, MD, has been named the Marilyn and Stanley M. Katz Dean at the Albert Einstein College of Medicine, effective October 2nd, 2023.

The board of directors of AbbVie Inc. declared a quarterly cash dividend of $1.48 per share.

Citius Pharmaceuticals, Inc. (“Citius” or the “Company”) (Nasdaq: CTXR) is pleased to announce the Company has received additional guidance from the U.S. Food and Drug Administration (FDA) regarding the planned resubmission of the Company’s Biologics License Application (BLA) for LYMPHIR™ (denileukin diftitox).